Clinical Trial

Identification of Chemotherapy-induced Peripheral Neuropathy

Study acronym: NEURO-BREAC
Completed
View on ClinicalTrials.gov →
Summary
The main goal of this trial is to identify the optimal cut-off score of a Scoring System to discriminate between moderate to severe chemotherapy-induced peripheral neuropathy (CIPN) and no CIPN in breast cancer survivors previously treated with taxane-based chemotherapy and adjuvant radiotherapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-22; most recent amendment 2026-05-23.
Status change: Not Yet Recruiting → Completed 2026-05-23
Trial Details
NCT Number NCT07148336
Lead Sponsor University Hospital Schleswig-Holstein
Collaborators: Zealand University Hospital
Conditions Breast Cancer
Enrollment 26 participants
Start Date 2025-12-01
Primary Completion 2025-12-15 (estimated)
Study Completion 2025-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-28